DeepUll is a technology company.
Deepull is developing technology for early detection of sepsis, providing 50 reportable results identifying pathogens and antibiotic resistance markers directly from blood in about 1 hour.
DeepUll has raised $79.0M across 3 funding rounds.
DeepUll has raised $79.0M in total across 3 funding rounds.
DeepUll has raised $79.0M in total across 3 funding rounds.
DeepUll's investors include Asabys Partners, Vsquared Ventures, Alta Life Sciences.
Deepull is a Barcelona-based medical diagnostics company developing the UllCORE system, a fully automated, culture-free diagnostic platform that delivers 50-52 reportable results for sepsis-causing pathogens and antibiotic resistance markers directly from whole blood in about 1 hour.[1][2][3] Targeting 95% of sepsis pathogens including bacteria, fungi, and resistance genes, it empowers hospital labs to provide faster results than traditional blood cultures, addressing a critical gap in early sepsis detection where timely diagnosis can reduce morbidity and mortality.[1][2][3] Founded in 2019-2020 and now at Series C stage, Deepull has raised over $100M total (including a €50M/$57M oversubscribed round in April 2025), serving hospitals and clinical labs with a benchtop analyzer featuring continuous loading for up to 8 samples, room-temperature reagents, and LIS connectivity.[2][3][4]
Deepull was founded in 2019 (per CB Insights) or 2020 (per company statements) in Barcelona, Spain, by the team behind STAT-Dx, a prior diagnostics venture sold to QIAGEN in 2018.[2][3][4] This experienced founding group leveraged their expertise in rapid molecular diagnostics to tackle sepsis, a life-threatening condition hard to diagnose due to dysregulated host responses to infection.[1] Early traction included seed funding of €3.5M in 2020 from investors like Alta Life Sciences and Kurma Partners, followed by Series A (€13M in 2022) and B rounds, building toward clinical validation.[4] Pivotal moments include FDA Breakthrough Device Designation for the UllCORE Bloodstream Infection Test in December 2024, enabling streamlined regulatory interactions, and recent €50M Series C in April 2025 to finalize studies and approvals.[2][3]
Deepull rides the wave of molecular diagnostics and precision medicine, specifically multiplex PCR for direct-from-sample pathogen ID, amid rising antimicrobial resistance and sepsis burdens (e.g., global challenges noted in literature).[1][3] Timing aligns with post-pandemic emphasis on rapid infectious disease testing, FDA Breakthrough status accelerating US entry, and Europe's healthtech boom—Barcelona's ecosystem supports scaleups like this.[2][4] Market forces favor it: sepsis affects millions annually with high mortality; traditional methods take days, while Deepull's 1-hour turnaround could transform ICUs. It influences the ecosystem by pushing culture-free tech, attracting investors like Panakès and Mérieux, and validating via prospective studies showing superior pathogen yield.[3][4]
Deepull is primed for global commercialization post-Series C, with clinical trials wrapping and FDA/EU approvals likely in 2026, potentially disrupting sepsis diagnostics dominated by slower incumbents.[2][3] Trends like AI-enhanced multiplexing and resistance tracking will amplify its edge, while expanding to other acute infections could drive adoption in resource-strapped hospitals. Its influence may grow via partnerships (e.g., Werfen), positioning it as a leader in accessible, high-impact healthtech—echoing its mission to empower labs for better patient outcomes through innovation.[1][4]
DeepUll has raised $79.0M across 3 funding rounds. Most recently, it raised $57.0M Series C in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $57.0M Series C | Asabys Partners, Vsquared Ventures | |
| Feb 1, 2023 | $18.0M Series B | Asabys Partners, Vsquared Ventures | |
| Jul 1, 2020 | $4.0M Series A | Alta Life Sciences |